BRPI1014635A2 - compostos heterocíclicos e de expansão para células-tronco hematopoiéticas - Google Patents

compostos heterocíclicos e de expansão para células-tronco hematopoiéticas

Info

Publication number
BRPI1014635A2
BRPI1014635A2 BRPI1014635A BRPI1014635A BRPI1014635A2 BR PI1014635 A2 BRPI1014635 A2 BR PI1014635A2 BR PI1014635 A BRPI1014635 A BR PI1014635A BR PI1014635 A BRPI1014635 A BR PI1014635A BR PI1014635 A2 BRPI1014635 A2 BR PI1014635A2
Authority
BR
Brazil
Prior art keywords
heterocyclic
stem cells
hematopoietic stem
expansion
compounds
Prior art date
Application number
BRPI1014635A
Other languages
English (en)
Inventor
Katsuaki Miyaji
Shunsuke Iwamoto
Taito Nishino
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of BRPI1014635A2 publication Critical patent/BRPI1014635A2/pt
Publication of BRPI1014635A8 publication Critical patent/BRPI1014635A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
BRPI1014635A 2009-06-04 2010-06-04 compostos heterocíclicos e agentes de expansão para células-tronco hematopoiéticas BRPI1014635A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009135495 2009-06-04
PCT/JP2010/059552 WO2010140685A1 (ja) 2009-06-04 2010-06-04 ヘテロ環化合物及び造血幹細胞の増幅剤

Publications (2)

Publication Number Publication Date
BRPI1014635A2 true BRPI1014635A2 (pt) 2016-04-05
BRPI1014635A8 BRPI1014635A8 (pt) 2016-10-11

Family

ID=43297817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014635A BRPI1014635A8 (pt) 2009-06-04 2010-06-04 compostos heterocíclicos e agentes de expansão para células-tronco hematopoiéticas

Country Status (9)

Country Link
US (2) US20120128640A1 (pt)
EP (1) EP2439204B1 (pt)
JP (1) JP5737177B2 (pt)
CN (1) CN102448949B (pt)
AU (1) AU2010254920C1 (pt)
BR (1) BRPI1014635A8 (pt)
CA (1) CA2760655C (pt)
IL (1) IL216131A0 (pt)
WO (1) WO2010140685A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435496B2 (en) * 2005-01-12 2008-10-14 Toyota Motor Engineering & Manufacturing North America, Inc. Anhydrous proton conductor based on heterocycle attached to a polymer backbone
KR102031386B1 (ko) 2011-10-03 2019-10-11 닛산 가가쿠 가부시키가이샤 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법
DE102012103405A1 (de) * 2012-04-18 2013-10-24 Heinrich-Pette-Institut Desoxyhypusin-Synthase-Inhibitoren
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Nk細胞の調製方法
WO2019196816A1 (zh) * 2018-04-13 2019-10-17 诺未科技(北京)有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN110972481B (zh) * 2018-09-17 2020-10-20 诺未科技(北京)有限公司 一种组合物及其用途
AU2020316632A1 (en) * 2019-07-19 2022-02-24 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)
US20230279440A1 (en) 2020-05-06 2023-09-07 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
EP4146812A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
WO2022085781A1 (ja) * 2020-10-23 2022-04-28 日産化学株式会社 造血障害の治療剤
CN114196632A (zh) * 2021-11-02 2022-03-18 济南赛尔生物科技股份有限公司 一种高效体外培养造血干细胞的培养基

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5605822A (en) 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
AU759522C (en) 1998-02-17 2005-05-12 Gamida Cell Ltd. Method of controlling proliferation and differentiation of stem and progenitor cells
JP2000023674A (ja) 1998-07-13 2000-01-25 Kirin Brewery Co Ltd 分化を抑制するペプチドと造血幹細胞増殖法
JP4453135B2 (ja) 1999-12-09 2010-04-21 東ソー株式会社 造血細胞の新規増幅剤
JP2004222502A (ja) * 2003-01-17 2004-08-12 Asahi Kasei Corp 造血幹細胞増幅法
UA82695C2 (uk) 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
JP4651282B2 (ja) * 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
EP1845090A4 (en) 2004-12-14 2009-11-11 Nissan Chemical Ind Ltd AMIDE COMPOUND AND THROMBOPOIETINE RECEPTOR ACTIVATOR
ZA200710465B (en) * 2005-07-15 2009-08-26 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoletin receptor activators
US7968542B2 (en) 2005-07-15 2011-06-28 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
EP1904488B1 (en) * 2005-07-20 2013-03-06 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
CA2635580A1 (en) 2005-12-30 2007-07-12 Alantos Pharmaceuticals Holding, Inc. Substituted bis-amide metalloprotease inhibitors
JP2009040692A (ja) 2007-08-06 2009-02-26 Hiroshima Univ ヒト末梢血由来cd133/cd34陽性細胞移植による筋損傷の修復
US20090142482A1 (en) 2007-11-30 2009-06-04 Xerox Corporation Methods of Printing Conductive Silver Features
EP2228435A4 (en) * 2007-12-05 2013-01-23 Nissan Chemical Ind Ltd METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
EP2233561A4 (en) * 2007-12-05 2013-01-16 Nissan Chemical Ind Ltd METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
WO2009072635A1 (ja) * 2007-12-06 2009-06-11 Nissan Chemical Industries, Ltd. ヘテロ環化合物による造血幹細胞の増幅方法

Also Published As

Publication number Publication date
EP2439204A4 (en) 2012-06-20
US9328085B2 (en) 2016-05-03
CA2760655C (en) 2018-03-06
AU2010254920A1 (en) 2011-11-24
JPWO2010140685A1 (ja) 2012-11-22
CA2760655A1 (en) 2010-12-09
WO2010140685A1 (ja) 2010-12-09
JP5737177B2 (ja) 2015-06-17
US20120128640A1 (en) 2012-05-24
EP2439204A1 (en) 2012-04-11
EP2439204B1 (en) 2017-01-04
CN102448949B (zh) 2014-09-03
BRPI1014635A8 (pt) 2016-10-11
IL216131A0 (en) 2012-01-31
AU2010254920C1 (en) 2016-03-10
CN102448949A (zh) 2012-05-09
US20130245255A1 (en) 2013-09-19
AU2010254920B2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
BRPI1014635A2 (pt) compostos heterocíclicos e de expansão para células-tronco hematopoiéticas
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
DK2411507T3 (da) Ekspansion af nk-celler
BRPI0921799A2 (pt) compostos que expandem células-tronco hematopoéticas
BRPI1011127A2 (pt) métodos para o cultivo de células tronco e células progenitoras
FI20096288A0 (fi) Formulations and methods for culturing stem cells
BRPI1013829A2 (pt) composições e métodos para fermentação de biomassa
ES2626492T8 (es) Procedimiento para la expansión de células T
SE0950586L (sv) Förbättrad odling av stamceller
BRPI1014708A2 (pt) dihidropirimidinonas para uso como inibidores de bace2
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
DK3043181T3 (da) Markører af akutte myeloid-leukæmi-stamceller
BRPI0810558A2 (pt) Armazenador para transplante
EP2094839A4 (en) EXPANSION OF HEMATOPOIETIC STEM CELLS
BRPI0907608A2 (pt) Formulas dinâmicas para células de planilha
BRPI0823079A2 (pt) Unidade flutuante para aramazenamento de gás
BRPI0913925A2 (pt) Diferenciação de células-tronco pluripotentes
BRPI1015367A2 (pt) imidazotiodiazois para uso como inibidores de cinase
DK3346004T3 (da) Amylasepolypeptider
IL220519A0 (en) Expansion medium for cd34-negative stem cells
BRPI0820915A2 (pt) método para expandir células tronco hematopoéticas usando composto heterocíclico
DK2403764T3 (da) Opbevaringsæske
BR112012003584A2 (pt) método e disposito para utilização de biomassa
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas
DK2061877T3 (da) Differentiering af stamceller

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.